Enterprise Value
177.2M
Cash
231.7M
Avg Qtr Burn
-22.12M
Short % of Float
8.75%
Insider Ownership
0.84%
Institutional Own.
84.04%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MRT-2359 Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1/2 Data readout |